Jim has been a partner of Domain since its inception in 1985. Jim has more than 45 years of experience with venture and emerging growth companies.
In the course of his experience, he has been involved in the creation and successful development at the board level of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Cadence Pharmaceuticals, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, NuVasive, Pharmion and Volcano. Present board memberships include Applied Proteomics, Astute Medical, aTyr Pharma, Axial Biotherapeutics, ChromaCode, Clovis Oncology, Gene Sciences, IntegenX and Ocunexus Therapeutics.
Prior to Domain, Jim was a former managing director of Rothschild Inc., where he was directly involved at a senior level with Rothschild/New Court venture capital activities. Previous to that, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. Jim was an engineering manager with RCA Corporation, during which time he received the David Sarnoff Fellowship. He received his BSE from Princeton University and his MSE and Ph.D. in electrical engineering from the University of Pennsylvania.
Jim currently serves on the board of directors of the Prostate Cancer Foundation and the SANFORD BURNHAM PREBYS Medical Discovery Institute. He is also on the advisory boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Caltech Division of Chemistry and Chemical Engineering.